ZIVO Bioscience, Inc. (ZIVO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ZIVO Bioscience, Inc. (ZIVO) trades at $3.95 with AI Score 58/100 (Grade B). ZIVO Bioscience, Inc. is a biotechnology company focused on the research and development of bioactive ingredients derived from proprietary algae cultures. Market cap: $15.4M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ZIVO: ZIVO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZIVO against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ZIVO: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ZIVO Bioscience, Inc. (ZIVO) Healthcare & Pipeline Overview
ZIVO Bioscience, Inc. operates in the biotech and agtech sectors, focusing on developing and licensing natural bioactive ingredients from proprietary algae cultures. Its intellectual property portfolio supports applications in animal and human health, targeting manufacturers in the dietary supplement and medical food industries, with a current market capitalization of $15.4M.
What Is the Investment Thesis for ZIVO?
ZIVO Bioscience, Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its proprietary algae-based platform and diverse potential applications. The company's small market capitalization ($0.04 billion) reflects its early stage of development and inherent risks. Key value drivers include successful licensing agreements for its bioactive ingredients and positive clinical trial results demonstrating efficacy in target applications. Growth catalysts include expanding its intellectual property portfolio and securing partnerships with established manufacturers in the animal and human health markets. However, potential investors may want to evaluate the company's negative profit margin (-4059.7%), limited financial resources, and the challenges associated with bringing novel biotechnology products to market. The company's beta of 0.33 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
ZIVO Key Highlights
Market capitalization of $15.4M, reflecting its early-stage growth phase.
- Gross margin of 31.7%, indicating potential for profitability as sales increase.
- Operates in the biotech and agtech sectors, targeting high-growth markets for natural health solutions.
- Intellectual property portfolio includes proprietary algal and bacterial strains, providing a competitive advantage.
- Focus on licensing and selling bioactive ingredients, offering a capital-efficient business model.
Who Are ZIVO's Competitors?
ZIVO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACHFF Arch Biopartners Inc. | $0.71 | -10.69% | $48.2M | 38 |
| AIRDF Rocket Doctor AI Inc. | $0.44 | -2.99% | $42.4M | 56 |
| CLTEF Calliditas Therapeutics Ab | $0.18 | -0.39% | $10.8M | 45 |
| HBPCF Helix BioPharma Corp. | $1.71 | +0.00% | $131M | 45 |
| INNMF Amplia Therapeutics Limited | $0.10 | -8.70% | $53.9M | 48 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZIVO's Key Strengths?
Proprietary algae strains and bioactive ingredients.
- Intellectual property portfolio.
- Potential applications in multiple markets (animal, human, medical food, cosmetics).
- Capital-efficient licensing business model.
What Are ZIVO's Weaknesses?
Small market capitalization and limited financial resources.
- Negative profit margin.
- Reliance on licensing agreements for revenue generation.
- Early stage of development and unproven commercial success.
What Could Drive ZIVO Stock Higher?
Announcement of new licensing agreements with animal or human health manufacturers (2026-2027).
- Publication of clinical trial results demonstrating the efficacy of ZIVO's bioactive ingredients (2026-2028).
- Expansion of intellectual property portfolio through new patent filings.
- Development of new product applications for ZIVO's algal biomass.
- Increasing market awareness of algae-based solutions and natural health products.
What Are the Key Risks for ZIVO?
Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure licensing agreements or commercialize its products.
- Competition from established players in the biotechnology and agtech sectors.
- Regulatory hurdles and lengthy approval processes.
- Limited financial resources and need for additional funding.
- Dependence on a small number of key personnel.
What Are the Growth Opportunities for ZIVO?
- Expansion into the human dietary supplement market: ZIVO has the opportunity to leverage its algal biomass to develop and market novel dietary supplements for human consumption. ZIVO can capitalize on this trend by formulating supplements targeting specific health needs, such as immune support, anti-aging, and gut health. Timeline: 2026-2028.
- Development of animal health products: ZIVO's bioactive ingredients have potential applications in animal health, including solutions for poultry gut health, bovine mastitis, and canine joint health. The global animal health market is a multi-billion dollar industry, driven by the increasing demand for animal protein and the growing pet population. ZIVO can partner with animal health companies to develop and commercialize products based on its proprietary ingredients. Timeline: 2026-2029.
- Licensing agreements with medical food manufacturers: ZIVO can pursue licensing agreements with medical food manufacturers to incorporate its bioactive ingredients into specialized nutritional products for patients with specific medical conditions. The medical food market is a growing segment of the healthcare industry, driven by the increasing prevalence of chronic diseases and the demand for personalized nutrition. Timeline: 2027-2030.
- Strategic partnerships with cosmetic companies: ZIVO's algal biomass has potential applications in the cosmetic industry, including products supporting skin health and anti-aging. The global cosmetics market is a multi-billion dollar industry, driven by the increasing demand for natural and sustainable beauty products. ZIVO can partner with cosmetic companies to develop and commercialize skincare products based on its proprietary ingredients. Timeline: 2027-2029.
- Expanding intellectual property portfolio: ZIVO can strengthen its competitive advantage by continuing to invest in research and development and expanding its intellectual property portfolio. This includes filing new patents for its algal strains, bioactive molecules, and production techniques. A strong IP portfolio will protect ZIVO's innovations and attract potential partners and investors. Timeline: Ongoing.
What Threats Does ZIVO Face?
- Competition from established players in the biotechnology and agtech sectors.
- Regulatory hurdles and lengthy approval processes.
- Patent challenges and intellectual property infringement.
- Fluctuations in commodity prices and supply chain disruptions.
What Are ZIVO's Competitive Advantages?
- Proprietary algae cultures and bioactive ingredients.
- Intellectual property portfolio of patents and patent-pending inventions.
- Specialized knowledge and expertise in algal cultivation and bioactive molecule extraction.
What Does ZIVO Do?
ZIVO Bioscience, Inc., established in 2014 (formerly Health Enhancement Products, Inc.), is a research and development company specializing in the discovery, development, and commercialization of bioactive ingredients derived from its proprietary algae cultures. Headquartered in Bloomfield Hills, Michigan, ZIVO operates at the intersection of biotech and agtech, focusing on applications in both animal and human health. The company's core business model centers around licensing and selling these natural ingredients to manufacturers in the animal, human, dietary supplement, and medical food industries. ZIVO's intellectual property portfolio includes proprietary algal and bacterial strains, biologically active molecules and complexes, production and cultivation techniques, and patented or patent-pending inventions. These assets support a range of potential product applications, including solutions for poultry gut health, bovine mastitis, canine joint health, and human immune modification. Additionally, ZIVO explores the use of algal biomass for human consumption and in products supporting skin health and anti-aging. The company's focus on natural bioactive ingredients positions it within the growing market for health and wellness products derived from sustainable sources.
What Products and Services Does ZIVO Offer?
- Researches and develops natural bioactive ingredients.
- Cultivates proprietary algae cultures.
- Licenses and sells bioactive ingredients to manufacturers.
- Targets the animal health market with solutions for poultry, bovine, and canine health.
- Develops ingredients for human dietary supplements.
- Explores applications in medical foods and cosmetics.
How Does ZIVO Make Money?
- Licensing proprietary bioactive ingredients to manufacturers.
- Selling algal biomass for various applications.
- Developing and patenting new algal strains and production techniques.
What Industry Does ZIVO Operate In?
ZIVO Bioscience, Inc. operates within the biotechnology and agtech sectors, which are characterized by rapid innovation, increasing demand for natural and sustainable products, and intense competition. ZIVO's focus on algae-derived bioactive ingredients aligns with the growing trend towards natural and plant-based solutions in the health and wellness industries. Competitors include companies developing alternative protein sources, animal health products, and dietary supplements. ZIVO's success will depend on its ability to differentiate its products, secure strategic partnerships, and navigate the complex regulatory landscape.
Who Are ZIVO's Key Customers?
- Animal health product manufacturers.
- Human dietary supplement manufacturers.
- Medical food manufacturers.
- Cosmetic companies.
Forward Outlook
Wall Street analysts project ZIVO Bioscience, Inc. revenue of about $1.2M for fiscal 2026, with EPS near $-1.08.
Earnings Track Record
ZIVO Bioscience, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 9.9% below estimates on average.
Financial Health
ZIVO Bioscience, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for ZIVO Bioscience, Inc. stands at 159.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -16.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -33.6%, the inverse of the P/E and a quick read on earnings relative to price.
ZIVO Bioscience, Inc. (ZIVO) Valuation Context
Valued at $15.4M, ZIVO is classified as a micro-cap stock. Relative to its peer group, ZIVO's quantitative score of 58/100 is above the peer average of 46/100.
Company Profile
ZIVO Bioscience, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Troy, US. The company is led by CEO John Bernard Payne. ZIVO has traded publicly since 2003.
ZIVO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in ZIVO's growth potential, suggesting strong belief in the company's future.
- Community sentiment has shifted positively, with discussions highlighting the innovative aspects of ZIVO's product pipeline.
- Recent collaborations in the biotech sector have raised expectations for ZIVO's market position, enhancing its credibility.
- The growing interest in health and wellness products aligns well with ZIVO's focus, positioning it favorably in a booming market.
Bear Case
- Concerns about regulatory hurdles in the biotech industry could create uncertainty around ZIVO's product approvals and market entry.
- Some community members express skepticism regarding ZIVO's ability to scale operations effectively, reflecting doubts about execution.
- Recent market volatility in the biotech sector has led to cautious sentiment, with some traders wary of potential downturns.
- Insider selling activity has raised flags among investors, leading to increased scrutiny of the company's internal dynamics.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $65,625 | -$1M | -$0.27 |
Based on FMP financials and quantitative analysis
ZIVO Latest News
No recent news available for ZIVO.
ZIVO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZIVO.
Price Targets
Wall Street price target analysis for ZIVO.
ZIVO MoonshotScore
What does this score mean?
The MoonshotScore rates ZIVO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John Bernard Payne
CEO
John Bernard Payne serves as the CEO of ZIVO Bioscience, Inc. His background includes experience in managing and growing companies, though specific details of his career history prior to ZIVO are not provided. He is responsible for the overall strategic direction and operational management of the company, guiding its research and development efforts and commercialization strategies.
Track Record: Under John Bernard Payne's leadership, ZIVO Bioscience, Inc. has focused on developing and expanding its intellectual property portfolio related to algae-based bioactive ingredients. Key milestones include securing patents for its proprietary algal strains and production techniques, as well as pursuing licensing agreements with manufacturers in the animal and human health markets. However, the company has yet to achieve sustained profitability.
ZIVO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ZIVO Bioscience, Inc. may not meet the minimum financial standards or reporting requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Trading on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and wide bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher risk of delisting or bankruptcy.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review the company's financial statements (if available).
- Assess the company's management team and track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Check for any legal or regulatory issues.
- Consult with a qualified financial advisor.
- Patents and intellectual property protection.
- Scientific publications or research collaborations.
- Existence of a functional website and investor relations materials.
- Involvement of experienced management team.
- Third-party validation or endorsements.
Common Questions About ZIVO (Healthcare)
What does the AI Score mean for ZIVO?
ZIVO holds an AI Score of 58/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. ZIVO Bioscience, Inc. is a biotechnology company focused on the research and development of bioactive ingredients derived from proprietary algae cultures. The company aims to license and sell these …
What does ZIVO Bioscience, Inc. do?
ZIVO Bioscience, Inc. is a biotechnology company that focuses on researching, developing, and commercializing natural bioactive ingredients derived from its proprietary algae cultures. The company operates by licensing and selling these ingredients to manufacturers in the animal, human, dietary supplement, and medical food industries.
What do analysts say about ZIVO stock?
As of March 16, 2026, there is no readily available analyst coverage for ZIVO Bioscience, Inc. due to its small market capitalization and OTC listing. Key valuation metrics, such as price-to-earnings ratio (-4.09), should be interpreted with caution given the company's negative profitability. Growth considerations include the successful commercialization of its bioactive ingredients and the ability to secure strategic partnerships.
What are the main risks for ZIVO?
ZIVO Bioscience, Inc. faces several risks inherent to the biotechnology industry and its specific business model. These include the risk of failing to secure licensing agreements for its bioactive ingredients, competition from larger and more established companies, regulatory hurdles and lengthy approval processes, and the need for additional funding to support its research and development efforts.
What are the key factors to evaluate for ZIVO?
ZIVO Bioscience, Inc. (ZIVO) holds an AI score of 58/100 (moderate). presents a speculative investment opportunity within the biotechnology sector, driven by its proprietary algae-based platform and diverse potential applications. Not financial advice.
How frequently does ZIVO data refresh on this page?
ZIVO's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZIVO's recent stock price performance?
ZIVO Bioscience, Inc. (ZIVO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary algae strains and bioactive ingredients. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZIVO overvalued or undervalued right now?
ZIVO Bioscience, Inc. (ZIVO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZIVO before investing?
Before investing in ZIVO Bioscience, Inc. (ZIVO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 16, 2026.
- OTC market data may be limited or less reliable than exchange-listed data.